Lupin Ltd - Share Price
LUPIN
Lupin LtdFinancials
Lupin LtdNews & Updates
Lupin launches authorized generic version of Duexis in the US
Sep 16,2021 10:52 AM
Ibuprofen and Famotidine Tablets (RLD: Duexis) had estimated annual sales of USD 765 million in the U.S. (IQVIA MAT July 2021).
Lupin board nods to settle litigations in Glumetza matter Sep 16,2021
Lupin launches rheumatoid arthritis treatment drug in US Sep 15,2021
Nifty Pharma stocks steady amid bullish markets; Dr Reddy's, Auro Pharma outperform Sep 14,2021
Nifty Pharma under pressure on broad-based selloff; Aurobindo Pharma, Dr Reddy's drag Sep 13,2021
Lupin rises after partnership for new therapy for highly drug-resistant TB Sep 06,2021
Meeting Type
Meeting Date
| Resolution Type | Description Of Resolution | IiAS Recommendation |
|---|
Peer Comparison
| Name | LTP | PE | Mar Cap | NP Qtr | Div. Yld | Sales Qtr | BV |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | 769.90 | 87.73 | 184,808.78 | 419.30 | 0.97 | 3,312.54 | 104.36 |
| Divis Laboratories Ltd | 5,122.80 | 67.55 | 136,069.90 | 551.97 | 0.39 | 1,950.16 | 349.25 |
| Dr Reddys Laboratories Ltd | 4,884.55 | 49.31 | 81,345.47 | 413.40 | 0.51 | 3,410.10 | 1,032.60 |
| Cipla Ltd | 954.05 | 29.05 | 76,966.86 | 791.77 | 0.52 | 3,948.33 | 247.04 |
| Gland Pharma Ltd | 3,962.90 | 63.11 | 65,258.82 | 350.68 | 0.00 | 1,153.90 | 359.44 |
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Lupin LtdSummary & Reports
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.Lupin Ltd was incorporated in th... More
Registered Office
Kalpataru Inspire 3rd Floor,Off Western Exp HW Santacruz-E,Mumbai, Maharashtra,400055
Tell. : +91-22-6640 2323
Website : http://www.lupin.com
Email : info@lupin.com
Registrar Office
C-101 247 Park, Vikhroli West, Mumbai-400083 INDIA
Tell. : +91-22-49186000
Website : www.linkintime.com
Email : rnt.helpdesk@linkintime.co.in
Reports by lupin-ltd-share-price
Latest Release by lupin-ltd-share-price
Result Express
Lupin Ltd's Q3FY19 consolidated net profit declines 14.1% yoy to Rs190.47cr : Misses Estimates
Sep 18, 2021 10:43 PM
The company’s consolidated revenue stood at Rs4,504.87cr, up 13.31% yoy and 15.78% qoq.
Shareholding Snapshot
Loading ...
| Jun - 2021 | |
|---|---|
| Promoter | - |
| Foreign | 0.28% |
| Indian | 46.55% |
| Total Promoter | 46.84% |
| Non Promoter | - |
| Institutions | 40.69% |
| Non-Institutions | 12.47% |
| Total Non-Promoter | 53.16% |
| Custodian | 0.00% |
| Total | 100% |
Corporate Action
Purpose
AGM
Exp. Date
11 Aug 2021
Annc. Date
15 Jul 2021
AGM 11/08/2021Proceedings at the Thirty-Ninth Annual General Meeting (AGM) pursuant to Regulation 30... More
Purpose
Board Meeting
Exp. Date
10 Aug 2021
Annc. Date
30 Jul 2021
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on... More
Purpose
Dividend
Annc. Date
13 May 2021
Effective. Date
27 Jul 2021
Divi. Type
Final
Divi.(%)
325
Divi. Amt.
6.5
Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 12,... More
